SAB Biotherapeutics (SABS) Operating Leases (2020 - 2026)

SAB Biotherapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Operating Leases fell 12.01% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 12.01% YoY) and the FY2025 annual result came in at $1.9 million, up 223.04% from the prior year.
• Operating Leases was $2.2 million for Q1 2026 at SAB Biotherapeutics, up from $1.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $2.5 million in Q1 2025 and bottomed at $227652.0 in Q1 2023.
• A 5-year average of $1.2 million and a median of $772605.0 in 2022 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases tumbled 87.08% — and 2025, when it surged 344.91%.
• SAB Biotherapeutics' Operating Leases stood at $361225.0 in 2022, then soared by 76.01% to $635777.0 in 2023, then decreased by 8.59% to $581148.0 in 2024, then soared by 223.04% to $1.9 million in 2025, then gained by 15.64% to $2.2 million in 2026.
• Business Quant data shows SABS's Operating Leases at $2.2 million in Q1 2026, $1.9 million in Q4 2025, and $2.0 million in Q3 2025.